Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Analyst Comment

Aiforia selected to provide AI-assisted diagnostics solutions in Castilla y León, Spain

By Juha KinnunenAnalyst
Aiforia Technologies

Translation: Original comment published in Finnish on 7/24/2024 at 7:20 am EEST.

The regional health management of Castilla y León in Spain has chosen Aiforia as its partner for AI-based diagnostics. The collaboration involves the use of selected Aiforia AI solutions for the analysis of tissue samples, e.g., from breast, prostate, and lung cancer patients. The total value of the contract for Aiforia is around 500 TEUR over three years, which means an annual billing of around 167 TEUR. This makes the contract quite significant for the company, but achieving the growth forecasts for the coming years will obviously require similar successes. 

Good proof of potential in Europe

The contract follows a call for tenders from the hospital district and an initiative to improve the diagnostic workflow in pathology laboratories. Aiforia has previously commented that the sales pipeline looks promising, particularly due to the large number of tenders in Europe (Italy, Spain, France, UK and Germany), of which this contract is a good indication. We understand that the contract that has now been awarded is a bid that the company had previously won but was delayed by the appeal process. Apparently, the local operator's complaints did not change the outcome. The project involves the use of an image management system provided by Sectra in combination with Aiforia's AI solutions. The cooperation strengthens Aiforia's position in the European market and demonstrates the added value and competitiveness of the company's AI solutions.  

The contract supports our growth forecasts

The total value of the contract represents just under 12% of our 2024 revenue forecast, but the value in terms of annual billings is obviously lower (less than 4% of our 2024 forecast). Our forecasts already include very strong growth and wins like this from Aiforia, so the contract does not lead to any forecast changes. Of particular importance to Aiforia's investment story is the demonstration of the company’s competitiveness through new customer wins, of which this agreement is another good example.

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Read more on company page

Key Estimate Figures29.05.2024

202324e25e
Revenue2.44.38.1
growth-%49.3 %80.1 %88.4 %
EBIT (adj.)-12.9-11.5-10.1
EBIT-% (adj.)-537.1 %-266.2 %-124.3 %
EPS (adj.)-0.50-0.41-0.36
Dividend0.000.000.00
Dividend %
P/E (adj.)neg.neg.neg.
EV/EBITDAneg.neg.neg.

Forum discussions

Without taking a position on the analysis itself, Nuways has a “buy” recommendation for almost every client, “under review” for a few, and a...
12 hours ago
by Verneri Pulkkinen
21
Pre-results update. Despite the share price, target €3.80 & Buy Summary: We remain upbeat on Aiforia’s Foundation Engine and its clinical and...
13 hours ago
by Opa
16
It is certainly possible that deals have also been made below the disclosure threshold. I believe there were a few such deals in H1 as well....
19 hours ago
by Jekkku
5
Well, the latest dip is quite clearly due to Faron (and Optomed). Probably the “retail crowd” got spooked, and many interested in these kinds...
19 hours ago
by JusaVaan
2
Faron is quite an extreme example, as its business seems to be a so-called binary case. It either succeeds or fails; there is no middle ground...
19 hours ago
by Puutaheinää
6
Just as @NanoCapKenobi says. Personally, I don’t invest in these still loss-making biotechs with anything other than a multi-year horizon. The...
19 hours ago
by Vino Pino
9
There is a general pessimistic atmosphere as there have been disappointments in the Finnish biotech scene. People no longer trust mere promises...
21 hours ago
by Optimistinen verkkapöksy
17
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.